Private Advisor Group LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Private Advisor Group LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 21,717 shares of the biopharmaceutical company’s stock, valued at approximately $829,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. CWM LLC boosted its holdings in Halozyme Therapeutics by 123.2% during the 1st quarter. CWM LLC now owns 848 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 468 shares during the period. Belpointe Asset Management LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth approximately $50,000. Harbour Investments Inc. purchased a new position in shares of Halozyme Therapeutics in the fourth quarter worth $51,000. Quadrant Capital Group LLC boosted its position in Halozyme Therapeutics by 111.5% during the 4th quarter. Quadrant Capital Group LLC now owns 960 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 506 shares during the period. Finally, Point72 Hong Kong Ltd purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at about $156,000. 92.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on HALO shares. TheStreet raised Halozyme Therapeutics from a “c+” rating to a “b” rating in a research note on Tuesday, August 8th. The Goldman Sachs Group cut Halozyme Therapeutics from a “buy” rating to a “neutral” rating and boosted their target price for the company from $43.00 to $45.00 in a research note on Monday, July 24th. Piper Sandler raised their price target on Halozyme Therapeutics from $46.00 to $48.00 in a research note on Wednesday, August 9th. Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $60.00 to $61.00 and gave the company an “overweight” rating in a research report on Thursday, August 10th. Finally, StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $54.27.

Check Out Our Latest Research Report on Halozyme Therapeutics

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $42.69, for a total transaction of $426,900.00. Following the transaction, the chief executive officer now owns 623,666 shares in the company, valued at $26,624,301.54. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold 80,000 shares of company stock worth $3,345,700 over the last three months. 2.30% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $42.98 on Thursday. The company has a market cap of $5.67 billion, a price-to-earnings ratio of 25.13, a P/E/G ratio of 0.65 and a beta of 1.24. The business’s fifty day simple moving average is $40.56 and its two-hundred day simple moving average is $38.50. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $59.46. The company has a current ratio of 6.58, a quick ratio of 5.44 and a debt-to-equity ratio of 9.91.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.09. Halozyme Therapeutics had a return on equity of 254.75% and a net margin of 30.21%. The firm had revenue of $221.04 million for the quarter, compared to the consensus estimate of $201.91 million. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 2.5 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Read More

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.